Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration

PURPOSE: To determine the efficacy and safety of treating predominantly hemorrhagic age-related macular degeneration (AMD) with transconjunctival sutureless vitrectomy (TSV), tissue plasminogen activator (tPA), sulphur hexafluoride (SF6), and intravitreal bevacizumab. METHODS: Retrospective study, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Arias, Luis, Monés, Jordi
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Orginal Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827187/
https://www.ncbi.nlm.nih.gov/pubmed/20186279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827187/
https://www.ncbi.nlm.nih.gov/pubmed/20186279

Ejemplares similares